



National Securities Market Commission
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Colmenar Viejo (Madrid), May 15, 2019

Pursuant to Article 17 of Regulation (EU) n° 596/2014 on market abuse and Article 226 of the consolidated text of the Spanish Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, we hereby make the following **REGULATORY ANNOUNCEMENT**:

“In relation to Significant Facts n° 276.396 and 276.625 dated March 25, 2019 and April 1, 2019, respectively, Pharma Mar, S.A. announces that ASCO (American Society of Clinical Oncology) has selected abstract titled “Efficacy and safety profile of Lurbinectedin in second-line SCLC patients: results from a phase II single-agent trial” for the “Best of ASCO” meetings in the summer over three US cities and 30 others over 5 continents. Prior to that, this abstract will be the subject of an oral presentation at the ASCO Congress on June 1st at 1:15 PM Chicago time. Best of ASCO® is an educational initiative that condenses highlights from ASCO’s Annual Meeting into a two-day program. The purpose of this initiative is to increase global access to cutting-edge science.

Please find attached press release that will be distribute to the media today”.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com

ASCO selects lurbinectedin second line small cell lung cancer abstract for “Best of ASCO” program

- The abstract titled “Efficacy and safety profile of Lurbinectedin in second-line SCLC patients: results from a phase II single-agent trial” (Abstract 8906) has been selected by ASCO to be included in the “Best of ASCO” meetings taking place this summer.
- The abstract was also selected by ASCO for an oral presentation at the ASCO Annual Meeting and will be presented on June 1st at 1:15pm CST.

Madrid, 15 de mayo de 2019.- ASCO has hand selected PharmaMar's (MSE:PHM) abstract 8906 for the “Best of ASCO” meetings in the summer over three US cities and 30 others over 5 continents. The list of meetings can be seen at <https://meetings.asco.org/boa/join-us> and <https://meetings.asco.org/boa/officially-licensed-best-asco-meetings>. Prior to that, this abstract will be the subject of an oral presentation at the ASCO Congress, and will be presented on June 1st at 1:15 PM Chicago time.

Best of ASCO[®] is an educational initiative that condenses highlights from ASCO’s Annual Meeting into a two-day program. The purpose of this initiative is to increase global access to cutting-edge science. Abstracts were selected according to specific criteria and reflect research that is relevant and significant in oncology today. In addition to three domestic Best of ASCO[®] Meetings (Seattle, Austin, Baltimore), there will also be nearly thirty International and [Officially Licensed Best of ASCO[®] Meetings](#).

“It is an honor to be selected in this small group of presentations labeled “Best of ASCO”. We are hoping to be able to offer a new therapeutic option for patients and physicians, the first since over twenty years, in second line lung cancer” said **Luis Mora**, General Manager of the Oncology Unit at PharmaMar.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar



Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at www.pharmamar.com.

About lurbinectedin

Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000



Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com